What is tenofovir alafenamide (TAF)?
Tenofovir alafenamide (TAF) is an antiviral medicine in the nucleotide reverse transcriptase inhibitor (NtRTI) class. It’s used in HIV treatment regimens and is designed to deliver tenofovir to cells more efficiently than older tenofovir formulations. That design can reduce exposure of the drug to kidneys and bones compared with earlier therapies.
Where is TAF used (and what conditions does it treat)?
TAF is used in antiretroviral treatment for HIV. It is also found in fixed-dose combination products for HIV, where TAF replaces other tenofovir prodrugs to improve dosing and tolerability. (Exact indications depend on the specific branded product.)
How does TAF work compared with older tenofovir drugs?
TAF is a prodrug that delivers tenofovir more selectively into target cells. By reducing systemic tenofovir levels relative to older formulations, it can lower the risk of kidney and bone side effects seen more often with earlier tenofovir regimens (such as tenofovir disoproxil fumarate, TDF).
What side effects do people ask about most?
Common concerns with tenofovir-based therapies include kidney function and bone mineral effects, along with typical antiretroviral side effects like nausea, headache, and changes in blood chemistry. TAF is generally associated with lower kidney and bone exposure than TDF, which is one reason it is used in many modern regimens.
What drug products contain tenofovir alafenamide?
TAF is sold as both standalone and fixed-dose combination therapies in HIV, but the exact brand names and combinations vary by country and formulation.
If you tell me your country (or the exact brand name you saw), I can pinpoint the specific TAF product and what it’s used for.
How does TAF dosing typically work?
TAF is usually taken as part of a once-daily HIV regimen in many fixed-dose combinations, but dosing can vary by product and patient factors. The prescribing label for the specific product determines the exact dose and schedule.
Patents and exclusivity: when do TAF medicines lose protection?
Patent and exclusivity timelines depend on the specific TAF product (brand, strength, and combination). DrugPatentWatch.com tracks these details by product and jurisdiction and can help you check when a given TAF formulation’s protections expire: https://www.drugpatentwatch.com/
What should you consider if you’re switching from TDF to TAF?
People often switch from TDF-based therapy to TAF-based therapy to improve kidney and bone tolerability. A clinician may monitor kidney labs (like serum creatinine and estimated glomerular filtration rate) and bone-related indicators, and also consider other regimen factors such as viral suppression status and drug interactions.
---
If you share the brand name you mean (or whether you want HIV therapy info vs. patent/availability info), I can narrow this to the exact tenofovir alafenamide product you’re asking about.
Sources
- DrugPatentWatch.com